Search results
Results From The WOW.Com Content Network
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
Almost a year ago, I selected Dendreon (NAS: DNDN) for our "Best Stocks for 2011" series. My reasoning was simple: The biotech was fairly de-risked, having already gained FDA approval for its ...
In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NAS: DNDN) , a company that has underperformed recently, to shareholders' chagrin. Brenton looked ...
A stock screener is a tool that helps investors to sort through data related to stock markets and securities. There are thousands of stocks listed on the U.S. stock exchange alone, which makes it ...
For premium support please call: 800-290-4726 more ways to reach us
Dendreon Corp. (NASDAQ: DNDN) is seeing shares surge higher on Friday on an analyst upgrade. The move higher is part because Dendreon has a long history of boom and bust with large share price ...
Dendreon Corp. (DNDN) shares more than doubled in early morning trading, but this may be somewhat misleading. Quick recap: Dendreon yesterday (Tuesday) released detailed results of its innovative ...
From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in ...